Ibalizumab in combination with other antiretroviral(s) for multidrug-resistant HIV-1 infection
Ibalizumab in combination with other antiretroviral(s) has been developed for the treatment of adults infected with multidrug-resistant HIV-1 (MDR HIV-1). HIV is a virus that damages the cells in the immune system and weakens the ability to fight everyday infections and diseases. HIV-1 is the most common type of HIV infection, which is incurable but there are effective treatments that enable most infected people to live a healthy life. Antiretroviral medicines are used to treat HIV. There are however limited effective treatments for some treatment-experienced patients with extensive MDR HIV-1.
Cabotegravir in combination with rilpivirine long acting injection for the treatment of HIV-1 infection
Cabotegravir and rilpivirine long acting injections are in development for the treatment of HIV-1 patients that are considered clinically suitable for injectable therapy. HIV (Human Immunodeficiency Virus) is a type of viral infection caused by a virus referred as retrovirus. HIV-1 is the most common and highly communicable type of HIV. HIV is a lifelong, chronic disease that nowadays can be managed with antiretroviral therapies. Usually patients take between one and 4 or 6 tablets a day. Failing to do so will result in a weaken immune system and increased vulnerability to infections.
Baloxavir marboxil for treatment of influenza A or B infection in otherwise healthy patients aged 12 years and older
Baloxavir marboxil is the first new flu medication to be developed within the last 20 years. It works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines (oseltamivir) do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional treatment option for patients with influenza A or B infection and for people who have suspected oseltamivir-resistant influenza.
RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Cefiderocol for severe gram-negative infections
Cefiderocol is a new drug to treat severe infections, which are caused by a particular group of bacteria called gram-negative bacteria, which are increasingly resistant to many antibiotics. Infections such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patient stay in hospital …
Plazomicin for treatment of multi-drug resistant Gram-negative Enterobacteriaceae infections
Hospital acquired infections, such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase health costs. These infections are frequently caused by types of bacteria that are becoming increasingly resistant to commonly prescribed antibiotics. Resistance to antibiotics is …